New Customers Get 10% Off – Use Code: LUX10

Secretagogue Stack

Tesamorelin / IPA

5.0 Reviews

CJC/Ipa Blend

A peptide blend combining Tesamorelin and Ipamorelin designed to stimulate growth hormone release through complementary pathways, studied for metabolic and hormonal regulation in research models. Premium Research Peptide.

Original price was: $84.99.Current price is: $76.49.

2 Day FAST Shipping

99%+ Purity Tests

Ships from USA

USA Lab Tested

We accept :

Certificate of Analysis

Third Party Tested by Freedom Diagnostics

How Tesamorelin / IPA Works

The Science, Simplified

Dual-Pathway Growth Hormone Stimulation

This blend combines Tesamorelin and Ipamorelin to stimulate growth hormone release through two distinct pathways in the pituitary.
Key insight: Tesamorelin activates GHRH receptors to increase endogenous growth hormone production, while Ipamorelin activates ghrelin (GHS-R1a) receptors to trigger GH pulse release. Together, they create larger and more sustained GH pulses than either compound alone.
GE
Primary

Gene Expression

Epigenetic Modulation

Upregulates 59% of affected genes Activates 47 DNA repair genes Suppresses inflammatory pathways

COL
Strongest

Gene Expression

Epigenetic Modulation

Upregulates 59% of affected genes Activates 47 DNA repair genes Suppresses inflammatory pathways

Cu²⁺
Supportive

Gene Expression

Epigenetic Modulation

Upregulates 59% of affected genes Activates 47 DNA repair genes Suppresses inflammatory pathways

Synergistic Hormone Response

The combination produces a synergistic effect rather than a simple additive response.

Key insight: Research observations indicate higher IGF-1 increases (approximately 30–37% above single-agent use) and significantly enhanced GH peak response. This occurs because each peptide operates through separate signaling pathways, reducing overlap and receptor fatigue.

Pharmacokinetic Complementarity

Each peptide contributes a different timing profile to growth hormone signaling.

Key insight: Ipamorelin acts quickly to initiate GH pulses, while Tesamorelin provides more sustained signaling. This combination results in both rapid and extended stimulation of growth hormone release.

Wrinkle Reduction Comparison

Safety Profile from Research

What clinical studies report

This blend is considered a premium research subject due to its high selectivity and the established clinical history of Tesamorelin.

🧿 Common Digestive Issues

8–12%

Injection site irritation

mild

%

Temporary water retention

mild

%

Tingling or joint stiffness

mild

Safety Advantage

Low Side-Effect Profile

  • No strong evidence of cortisol or prolactin elevation from Ipamorelin
  • Small increases in fasting glucose reported with Tesamorelin
  • Effects are generally dose-dependent
  • Limited long-term combination-specific data beyond ~6 months

📊 Discontinuation Rates

🚫 Trial Exclusions

⚡ Regulatory Status

💡 Researcher Notes

Compound Information

Technical specifications for this 8 mg blend

🔬 Molecular Profile

What Is TESA/IPA?

Category

Growth hormone secretagogue

Type

GHRH analog + ghrelin receptor agonist

Tesamorelin

6mg

Ipamorelin

2 mg

Purity

≥99%

🧊 Storage Requirements

Stability Information

Store lyophilized form in a cold,

dry environment

After reconstitution:

Tesamorelin stable ~14 days

After reconstitution:

Ipamorelin stable ~28 days

Heat exposure may

reduce potency

Proper storage is critical to

maintain activity

📋Research Status

Development History

Classification

GHRH / GHSR dual-pathway blend

Primary focus

Growth hormone release and metabolic research

Evidence base

Mechanistic studies, Tesamorelin clinical trials, and observational combination data

WADA Status

Banned (S2. Hormone and Metabolic Modulators)

Clinical limitation

Large-scale randomized controlled trials on the exact blend are currently limited

Frequently Asked Questions

Common questions about Tesamorelin / IPA

In research, it’s all about synergy. Tesamorelin is great at telling the body to make growth hormone, but Ipamorelin is great at telling the body to release it. By using the Tesamorelin / Ipamorelin Blend, you get a significantly more powerful result than doubling the dose of either one individually.
Yes. Tesamorelin is the only peptide specifically noted for its ability to reduce visceral fat (the hard fat behind the abdominal wall). When paired with Ipamorelin, it becomes an ideal subject for metabolic research focusing on body composition and the "middle-age" metabolic slowdown.
CJC-1295 (No DAC) is a general-purpose GHRH. Tesamorelin is a more "premium" and potent GHRH analog that is specifically tailored for fat metabolism. While CJC/IPA is a great all-rounder, TESA/IPA is often considered the superior choice for fat-loss-centric protocols.
Growth hormone secretagogues can occasionally impact glucose metabolism. However, Tesamorelin was specifically designed to minimize this impact, making it one of the more "metabolically friendly" options for researchers studying subjects with insulin sensitivity concerns.
No. While Tesamorelin itself is FDA-approved for specific medical conditions (Egrifta), this specific 11mg/6mg blend is an investigational research compound. It is not intended for human use and is sold strictly for laboratory settings.

Sources & References

Peer-reviewed research

  • Important Research Notice

Not for human consumption. This product is sold exclusively for research and educational purposes. It is not intended to diagnose, treat, cure, or prevent any disease.

All clinical trial data and research findings presented on this page are sourced from peer-reviewed journals and official publications. They are provided for educational reference only and should not be interpreted as medical advice or product claims.

By purchasing this product, you confirm that you are a qualified researcher and will use it in accordance with all applicable laws and regulations.

My Account
Follow Us
Linkedin X-twitter Icon-instagram-1 Facebook-square